These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2677628)

  • 1. Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group.
    Buckley JD; Lampkin BC; Nesbit ME; Bernstein ID; Feig SA; Kersey JH; Piomelli S; Kim T; Hammond GD
    Med Pediatr Oncol; 1989; 17(5):382-90. PubMed ID: 2677628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
    Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
    J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
    Lazarus HM; Vogler WR; Burns CP; Winton EF
    Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
    Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
    Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative analysis of 3 therapeutic regimens based on the combination of an anthracycline and cytosine arabinoside for remission induction in myeloblastic leukemia].
    Sanz MA; Lorenzo JI; Sanz GF; Martín Aragonés G; Rafecas FJ; Martínez JA; Gomis F
    Sangre (Barc); 1988 Dec; 33(6):497-504. PubMed ID: 3247626
    [No Abstract]   [Full Text] [Related]  

  • 9. Daunorubicin 90 mg/m
    Portugal R; Lyrio R; Loureiro M; Urago K; Bard J; Borchardt A; Garnica M; Nucci M
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):527-531. PubMed ID: 28842139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive treatment of acute leukemia in adults 70 years of age and older.
    Walters RS; Kantarjian HM; Keating MJ; Estey EH; McCredie KB; Freireich EJ
    Cancer; 1987 Jul; 60(2):149-55. PubMed ID: 3474052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study.
    Ravindranath Y; Steuber CP; Krischer J; Civin CI; Ducore J; Vega R; Pitel P; Inoue S; Bleher E; Sexauer C
    J Clin Oncol; 1991 Apr; 9(4):572-80. PubMed ID: 2066754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.
    Liang R; Chiu E; Chan TK; Todd D
    Cancer Chemother Pharmacol; 1990; 26(5):380-2. PubMed ID: 2208581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
    Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
    Hayat M; Jehn U; Willemze R; Haanen C; Zittoun R; Monconduit M; Lowenberg B; Stryckmans P; Peetermans M; De Cataldo F
    Cancer; 1986 Aug; 58(3):617-23. PubMed ID: 3524789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
    Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L
    Blood; 1984 May; 63(5):1039-45. PubMed ID: 6201211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia.
    Pavlovsky S; Fernández I; Palau V; Santarelli MT; De Bellis R; Ruiz-Argüelles G; Brandalise S; Jiménez-Fonseca E
    Ann Oncol; 1991 Jun; 2(6):441-2. PubMed ID: 1768631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
    Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
    Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204.
    Amadori S; Ceci A; Comelli A; Madon E; Masera G; Nespoli L; Paolucci G; Zanesco L; Covelli A; Mandelli F
    J Clin Oncol; 1987 Sep; 5(9):1356-63. PubMed ID: 3476689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.